BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VOXZOGO® Growth Continued in the Second Quarter Driven by Global Demand Resulting in Increased Full Year 2023 Guidance Pivotal Program with VOXZOGO in New, Potential Second Indication, Hypochondroplasia, to Begin in the Fourth Quarter of 2023 U.S. Approval of ROCTAVIAN™ Received in the Second Quarter and Commercial Launch Underway; Commercial Launch in Europe Making Progress Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 % Change 2023 2022 % Change Total Revenues $        595.3 $        533.8 12 % $     1,191.7 $    1,053.2 13 % Total Enzyme Product Revenues (1) $        420.8 $        425.7 (1) % $        868.8 $       852.3 2 % VIMIZIM® Net Product Revenues $        177.4 $        173.3 2 % $        366.6 $       356.4 3 % VOXZOGO® Net Product Revenues $        113.3 $          34.4 229 % $        201.2 $         54.0 273 % NAGLAZYME® Net Product Revenues $          90.1 $        115.8 (22) % $        213.1 $       243.8 (13) % PALYNZIQ® Net Product Revenues $          74.9 $          61.6 22 % $        137.2 $       116.5 18 % KUVAN® Net Product Revenues $          50.6 $          57.6 (12) % $        101.1 $       116.9 (14) % ALDURAZYME® Net Product Revenues $          40.3 $          37.3 8 % $          74.7 $         61.7 21 % BRINEURA® Net Product Revenues $          38.1 $          37.7 1 % $          77.2 $         73.9 4 % GAAP Net Income (2) $          56.0 $          27.7 $        106.9 $       148.5 Non-GAAP Income (3) $        105.2 $          76.8 $        221.0 $       175.7 GAAP Diluted Earnings per Share (EPS) $          0.29 $          0.15 $          0.56 $         0.79 Non-GAAP Diluted EPS (4) $          0.54 $          0.41 $          1.14 $         0.93   June 30, 2023 December 31, 2022 Total cash, cash equivalents & investments $               1,556.7 $               1,625.4 (1) Enzyme-based products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM. (2) GAAP Net income in the first half of 2022 included a $89.0 million gain, net of taxes, related to the sale of the Rare Pediatric DiseasePriority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approvalof VOXZOGO.

BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date

BioMarin's stocks have underperformed the S&P500 index recently due to the investor rotation from defensive sectors to riskier ones and potential slowdown in M&A activity in the biotechnology sector. Despite this, BioMarin's business remains attractive with approvals for its two flagship drugs, Voxzogo and Roctavian, and potential inclusion in the S&P500 index could lead to a significant increase in stock price. I remain my bullish view on BMRN's shares with fair value of $118.

BioMarin: More Growth Is Coming

SAN RAFAEL, Calif. , July 12, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, July 31, at 4:30 p.m.

BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET

ImmunoGen

Navigating the choppy waters in the biotech sphere can be daunting, which makes it a challenge to hunt for the top high return biotech stocks. The journey to market approval, encumbered by volatile clinical trials and regulatory roadblocks, can be an uphill battle.

3 Biotech Stocks to Make Your ‘Get Rich' Dreams Come True

BioMarin NASDAQ: BMRN shares have been under pressure due to delays in approving its hemophilia A drug Roctavian. That is over.

Is BioMarin Ready To Rebound After FDA Approval Of Roctavian?

BioMarin Pharmaceutical Inc. received FDA approval for ROCTAVIAN for adults with severe Hemophilia A. Net product revenues of VOXZOGO grew by 346% year-over-year to $87.8 million. In the coming months U.S. and European Union will decide if VOXZOGO should be expanded to treat another 1,000 achondroplasia patients.

BioMarin: FDA Approval Of ROCTAVIAN And Massive VOXZOGO Sales Increase

Following FDA's approval, BioMarin's (BMRN) Roctavian becomes the first gene therapy for treating severe hemophilia A.

BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy

BioMarin Pharmaceutical Inc. BMRN, -3.57% received Food and Drug Administration approval of its gene therapy Roctavian to treat hemophilia A, the agency said late Thursday. The FDA said Roctavian was the first gene therapy to treat adults with severe hemophilia A, a serious genetic disorder that affects the gene that makes the protein that casues blood to clot, increasing the risk of uncontrolled bleeding.

FDA approves BioMarin's gene therapy drug for hemophilia

The U.S. Food and Drug Administration on Thursday approved BioMarin Pharmaceutical's gene therapy for hemophilia A, the company said, giving patients with the inherited bleeding disorder an option to reduce regular blood infusions.

US FDA approves BioMarin's gene therapy for hemophilia A

ROCTAVIAN is a One-Time, Single-Dose Treatment Available for Adults with Severe Hemophilia A to Control Bleeds ROCTAVIAN's Approval was Based on Durability, Efficacy and Safety Results from the Largest and Longest Phase 3 Study for a Gene Therapy for Hemophilia Majority of Patients Continued to Respond to ROCTAVIAN Treatment over 3 Years Conference Call and Webcast to be Held at 4:30 p.m. Eastern Time on Thursday, June 29, 2023  SAN RAFAEL, Calif.

U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A

A major catalyst may arrive tomorrow for BioMarin as the FDA announces whether it will approve hemophilia gene therapy Roctavian. The drug is already approved in Europe, although pricing disputes are hindering sales. That ought not to be a problem in the US. BioMarin generated >$2bn of revenues in 2022 and is guiding for ~$2.4bn in 2023. Newly approved achondroplasia therapy VOXZOGO is expected to become a blockbuster.

BioMarin: Decision Day For Hemophilia Gene Therapy Upcoming - Approval Likely

Ampio Pharmaceuticals Inc

Harmony Biosciences Holdings

The biotech sector will always house stocks with explosive upside potential. The very nature of the sector ensures that will continue to be the case.

3 Biotech Stocks to Buy With Explosive Upside Potential

New Data to be Presented for ROCTAVIAN from Phase 3 GENEr8-1 Study, Including Data on the Impact of ROCTAVIAN on Quality of Life and M usculoskeletal Health  for Adults with Severe Hemophilia A SAN RAFAEL, Calif. , June 22, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today announced it will present new data from the ROCTAVIAN™ (valoctocogene roxaparvovec) gene therapy clinical trial program.

BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress

Gilead Sciences

Travere Therapeutics

Navigating the turbulent waters in the biotech space is no mean feat. With the sector's inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging.

3 Biotech Stocks That Could Skyrocket in the Next 12 Months

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report?

Novo Nordisk

When it comes to possibilities of outsized rewards, few sectors can beat out biotech stocks with blockbuster potential. Fundamentally, the underlying sector enjoys a massive footprint.

3 Biotech Stocks With Blockbuster Potential

ACADIA Pharma

Agios Pharmaceuticals

Amgen

ARK Genomic Revolution Multi-Sector ETF

VanEck Vectors Biotech ETF

CareDx

Exact Sciences

Exelixis

First Trust NYSE Arca Biotechnology Index Fund

FibroGen

iShares Nasdaq Biotechnology ETF

Ionis Pharma

IQVIA Hlds

Madrigal Pharmaceuticals

Moderna

Pacific Biosciences of California

Regeneron Pharmaceuticals

Seagen

Teladoc

TG Therapeutics

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Here are the five best biotech ETFs to invest in right now.

Investing in Biotech ETFs

PTC Therapeutics

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan. The post Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals appeared first on Investor's Business Daily.

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals

SAN RAFAEL, Calif. , May 4, 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Brian Mueller, Executive Vice President, Chief Financial Officer of BioMarin will present at the Bank of America 2023 Health Care Conference on Wednesday, May 10, 2023 at 3:40pm PT, in Las Vegas, NV.

BioMarin to Participate in Bank of America 2023 Health Care Conference

BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.

BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales

While the top- and bottom-line numbers for BioMarin (BMRN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say

Biomarin Pharmaceutical, Inc. (BMRN) Q1 2023 Earnings Call Transcript.

Biomarin Pharmaceutical, Inc. (BMRN) Q1 2023 Earnings Call Transcript

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.55 per share a year ago.

BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates

Growth of VOXZOGO® Accelerated with Rapid Uptake in Japan and Brazil Resulting in Increased Full-year 2023 Guidance Full-year 2023 Top-line and Bottom-line Financial Guidance Reaffirmed; ROCTAVIAN™ Net Product Revenue Guidance Adjusted for Full-year 2023 In Germany, Growing Pipeline of People with Severe Hemophilia A Getting Tested for ROCTAVIAN Treatment Eligibility; ROCTAVIAN U.S. Launch Preparations Underway Ahead of June 30 Prescription Drug User Fee Act (PDUFA) Target Action Date Financial Highlights  (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended March 31, 2023 2022 % Change Total Revenues $       596.4 $       519.4 15 % Total Enzyme Product Revenues (1) $       448.1 $       426.5 5 % VIMIZIM® Net Product Revenues $       189.2 $       183.0 3 % NAGLAZYME® Net Product Revenues $       123.0 $       128.0 (4) % VOXZOGO Net Product Revenues $         87.8 $         19.7 346 % PALYNZIQ® Net Product Revenues $         62.4 $         54.9 14 % KUVAN® Net Product Revenues $         50.5 $         59.3 (15) % BRINEURA® Net Product Revenues $         39.1 $         36.2 8 % ALDURAZYME® Net Product Revenues $         34.4 $         24.4 41 % GAAP Net Income (2) $         50.9 $       120.8 Non-GAAP Income (3) $       115.8 $         98.8 GAAP Diluted Earnings per Share (EPS) $         0.27 $         0.63 Non-GAAP Diluted EPS (4) $         0.60 $         0.52   March 31, 2023 December 31, 2022 Total cash, cash equivalents & investments $               1,492.7 $               1,625.4 (1) Enzyme-based products include ALDURAZYME, BRINEURA, NAGLAZYME, PALYNZIQ, and VIMIZIM. (2) GAAP Net income in the first quarter of 2022, included a $89.0 million net gain, net of taxes related to the sale of the Rare Pediatric Disease Priority Review Voucher (PRV) the Company received from the U.S. Food and Drug Administration (FDA) in connection with U.S. approval of VOXZOGO.

BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues

LONDON--(BUSINESS WIRE)--MiNA Therapeutics, the pioneer of small activating RNA (RNAa) therapeutics, today announced a multi-target research collaboration and option licensing agreement with BioMarin Pharmaceutical Inc. The collaboration will allow for the discovery, and potential development and commercialization of RNAa therapeutic candidates targeting a number of rare genetic diseases. Under the agreement, BioMarin will employ MiNA Therapeutics' proprietary RNAa algorithm and technology plat.

News for BioMarin Pharmaceutical Stock (BMRN)